Investigational drug · Phase 2
Peg-IFN-α
Also called: pegylated interferon
Not approved by FDA. In 6 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Chronic Hepatitis B, Chronic Hepatitis B Virus (HBV) Infection, Hepatitis B, Chronic.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
6
3 still active
All registered trials
147
Any phase or sponsor naming "Peg-IFN-α"
First trial start
2021
Jul 11, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Peg-IFN-α", any sponsor or status.
Conditions studied
As listed on its trial records.
- Chronic Hepatitis B
- Chronic Hepatitis B Virus (HBV) Infection
- Hepatitis B, Chronic
- For Treatment of Chronic Hepatitis B Virus Infection
- Chronic Hepatitis B Virus Infection
Approved drugs for the same conditions: Hepatitis B · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "Peg-IFN-α" as an intervention, largest first.
- The Clinical Cure Project of Chronic Hepatitis B in ChinaActive, not recruiting
Third Affiliated Hospital, Sun Yat-Sen UniversityAcademic, hospital or other
NCT04035837 · 30,000 participants (planned) · Start May 16, 2018 · Primary completion Dec 31, 2025
Drug: pegylated interferon-alfa · For: Hepatitis B, Chronic
Sites: Guangzhou, China
- A Study on the Pursuit of Sustained Clearance of HBsAg in Chronic Hepatitis B(CHB) Patients With Previous Interferon Treatment Using Pegylated Interferon AlphaNot yet recruiting
xieqingAcademic, hospital or other
NCT07537387 · 10,000 participants (planned) · Start Apr 30, 2026 · Primary completion Dec 31, 2029
Drug: PEG IFNα-2b monotherapy or combination therapy with NAs; NAs monotherapy group · For: Chronic Hepatitis b
Sites: Shanghai, China
Beijing 302 HospitalAcademic, hospital or other
NCT06926647 · 2,000 participants (planned) · Start May 1, 2025 · Primary completion Dec 15, 2028
Drug: Nucleos(t)ide Analogues; Interferon alfa and 1 more · For: HBV; Chronic Hepatitis b
Sites: Ankang, China; Anyang, China; Beihai, China · 85 sites in all
First Affiliated Hospital of Wenzhou Medical UniversityAcademic, hospital or other
NCT06368882 · 1,500 participants (planned) · Start Jan 1, 2024 · Primary completion Dec 31, 2028
Drug: Peg-Interferon α · For: Nonalcoholic Fatty Liver Disease; Chronic Hepatitis b
Sites: Ningbo, China; Rui’an, China; Wenzhou, China · 5 sites in all
- Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared With Peg-IFN Alfa-2a With Ribavirin in IFN Naive PatientsPivotal-lookingCompleted
Human Genome Sciences Inc.Industry
NCT00402428 · 1,331 participants · Start Dec 2006 · Primary completion Feb 2009
Drug: albumin interferon alfa-2b; peginterferon alfa-2a and 1 more · For: Chronic Hepatitis C
Sites: Birmingham, Alabama; Phoenix, Arizona; Fresno, California · 165 sites in all
- Interferon Alfa Following Surgery in Treating Patients With Stage III MelanomaPivotal-lookingStatus unknown
European Organisation for Research and Treatment of Cancer - EORTCResearch network
NCT00006249 · 1,258 participants · Start Jun 2000 · Primary completion Aug 2003
Drug: pegylated interferon alfa · For: Melanoma (Skin)
Sites: East Melbourne, Australia; Heidelberg West, Australia; Perth, Australia · 104 sites in all
- Efficacy of Polyethylene Glycol-Interferon Alfa-2B (PEG-Intron, SCH 54031) Compared to Interferon Alfa-2B in Participants With Chronic Hepatitis C (MK-4031-016)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT03537274 · 1,224 participants · Start Aug 5, 1997 · Primary completion Jul 23, 1999
Drug: PEG-Intron; Interferon Alfa-2B · For: Hepatitis C
- A Phase 3 Study of Telaprevir in Combination With Pegasys® and Copegus® in Treatment-Naive Subjects With Genotype 1 Hepatitis C Virus (HCV)Pivotal-lookingCompleted
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT00627926 · 1,095 participants · Start Mar 2008 · Primary completion May 2010
Drug: Pegylated Interferon Alfa 2a; Telaprevir and 1 more · For: Hepatitis C
Sites: Birmingham, Alabama; Phoenix, Arizona; Fresno, California · 116 sites in all
- Development and Validation of Models to Predict Functional Cure in Patients With CHB After Peg-IFN Based TherapyStatus unknown
Qilu Hospital of Shandong UniversityAcademic, hospital or other
NCT06196632 · 1,000 participants (planned) · Start Jan 6, 2024 · Primary completion Jul 31, 2024
Drug: Peginterferon-α; Nucleoside analogs · For: Hepatitis B, Chronic
Sites: Jinan, China
- Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared to Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients Geno2/3Pivotal-lookingCompleted
Human Genome Sciences Inc.Industry
NCT00411385 · 933 participants · Start Feb 2007 · Primary completion Oct 2008
Drug: albumin interferon alfa-2b; peginterferon alfa-2a and 1 more · For: Chronic Hepatitis C
Sites: Phoenix, Arizona; La Jolla, California; San Francisco, California · 159 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Established Versus Novel Strategies for Hepatitis B Functional Cure: A Cross-Regional Cost-Effectiveness Analysis of Pegylated Interferon and Bepirovirsen Add-on Therapy.
Chen J, Zhao S, Jia J, et al. · J Clin Exp Hepatol 2027
- Machine learning prediction of functional cure to pegylated interferon-alpha therapy in two HBV populations: Advantaged populations and HBeAg-negative patients.
Li J, Li H, Lin C, et al. · Virulence 2026
- Hepatitis B and D: Interferon-Based Therapy-For Clinical Trials or Standard of Care-Back to the Future?
Cargill Z, Janssen HLA, Asselah T, et al. · J Viral Hepat 2026
- Liver concentrations of JNJ-73763989 siRNA triggers in patients with chronic hepatitis B (CHB): The INSIGHT study panel 3 results.
Asselah T, Vilgrain V, Kakuda TN, et al. · Antivir Ther 2026
- Sequential combination of anti-PD-1 antibody and PEG-IFNα in chronic hepatitis B patients: correlates of HBsAg loss with enhanced T-cell responses.
Wang H, Zhang C, Li X, et al. · Emerg Microbes Infect 2026
- Group-based trajectory modeling for declines in hepatitis B surface antigen over time accurately identifies chronic hepatitis B patients achieving functional cure: a single-center cohort study in China.
Peng Y, Liu L, Wu X · Ann Med 2026
Also in development for Chronic Hepatitis B
- GST-HG141Phase 33 trials
Fujian Akeylink Biotechnology Co., Ltd. · Chronic Hepatitis b, Chronic Hepatitis B
- TAFPhase 33 trials
Gilead Sciences · HIV-1-infection, Chronic Hepatitis B
- TQA3605Phase 33 trials
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Chronic Hepatitis b, Chronic Hepatitis B, HBV Infection With LLV
- HRS-5635Phase 32 trials
Fujian Shengdi Pharmaceutical Co., Ltd. · Chronic Hepatitis B, Nucleos(t)Ide Analogue-suppressed HBeAg-negative Patients With Chronic Hepatitis B
- TVAX-008Phase 24 trials
Grand Theravac Life Sciences (Nanjing) Co., Ltd. · Chronic Hepatitis B, HBV Infection, Chronic Hepatitis B Virus
- HT-101Phase 23 trials
Suzhou HepaThera Biotech Co., Ltd. · Chronic Hepatitis B, Chronic Hepatitis B Virus Infection
- HT-102Phase 23 trials
Suzhou HepaThera Biotech Co., Ltd. · Chronic Hepatitis B, Chronic Hepatitis B Virus Infection
- NAsNucleoside analogs, acidPhase 23 trials
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Chronic Hepatitis B, HBV Infection With LLV
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.